LLR APC Meeting Minutes August 2026(388 KB) - LMSG/LLR APC minutes
Date added: 15th Sep 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| AFICAMTEN (Myqorzo®) (NEW) | Red | for treating symptomatic obstructive hypertrophic cardiomyopathy |
In line with NICE TA1181 |
| ATOGEPANT (Aquipta®) (NEW) | Green | For treating acute migraine |
In line with NICE TA1172 Funding from 30th July 2026 |
| BECLOMETASONE Inhaler - CFC free (UPDATED) | Green | Asthma |
QVAR® brand recommended for adults. Soprobec® brand recommended only for children. Clenil Modulite® inhalers are being discontinued. Patients prescribed Clenil Modulite® 50 microgram or 100 microgram inhalers should be switched to the equivalent strength of Soprobec®, in line with the local SBAR and Medicines Supply Notification (MSN)
Soprobec® provides a like-for-like dose of beclometasone dipropionate; however, it does not include a dose counter.
|
| CLESROVIMAB (NEW) | Red | RSV passive immunisation as per green book | |
| DEURUXOLITINIB (Leqselvi®) (NEW) | Red | for treating severe alopecia areata |
In line with TA1178
|
| DONEPEZIL (UPDATED) | Yellow | Alzheimer's disease |
In line with NICE NG 97 Orodispersible tablets are more cost-effective than the oral solution. However, Apozyl® 5mg remains more cost-effective in primary care. |
| DONIDALORSEN (Dawnzera®) (NEW) | Red | for preventing recurrent attacks of hereditary angioedema in people 12 years and over |
In line with NICE TA1183 Funding from 17th November 2026 |
| GLYCOPYRRONIUM BROMIDE CREAM (NEW) | Green | for treating severe primary axillary hyperhidrosis |
In line with NICE TA1175 Funding from 7th October 2026 |
| HYDROXYCHLOROQUINE (UPDATED) | Yellow | Dermatological conditions |
Retinal screening for hydroxychloroquine toxicity should be arranged in line with Royal College of Ophthalmologists guidance. Secondary care is responsible for ensuring appropriate monitoring is arranged. |
| HYDROXYCHLOROQUINE (UPDATED) | Yellow | Rheumatological disease |
Retinal screening for hydroxychloroquine toxicity should be arranged in line with Royal College of Ophthalmologists guidance. Secondary care is responsible for ensuring appropriate monitoring is arranged. |
| LENACAPAVIR (Sunlenca®) (UPDATED) | Red | multi-drug resistant HIV | |
| LIRAGLUTIDE (Diavic®) (UPDATED) | Green | Type 2 diabetes |
Diavic® is the preferred liraglutide formulation across LLR. Available only in line with NICE NG28 |
| LIRAGLUTIDE (Diavic®) | Yellow | Type 2 diabetes mellitus in children 10 years and over |
Diavic® is the preferred liraglutide formulation across LLR Available only in line with NICE NG28 |
| METHYLPHENIDATE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care and Net Formulary Note: Medikinet XL® – No new initiations from September 2026. Existing patients prescribed Medikinet XL should be switched to Ambinet XL at an appropriate clinical review. |
| NIRSEVIMAB (NEW) | Red | RSV passive immunisation as per green book | |
| SELADELPAR (Livdeli®) (NEW) | Red | for previously treated primary biliary cholangitis |
In line with NICE TA1171 Funding from 22nd September 2026 |
| TEPLIZUMAB (Tzield®) (NEW) | Red | for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes |
In line with NICE TA1176 Funding from 7th October 2026 |
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Yellow | For treating type 2 diabetes |
Once weekly preparation available only in line with NICE NG28 Not to be used alongside DPP-4 inhibitors First choice GLP-1 RA for T2DM new starts where BMI < 35 – SC semaglutide (Ozempic) First choice GLP-1 RA for T2DM new starts where BMI > 35 – SC semaglutide (Ozempic) or SC tirzepatide (Mounjaro) |
Other Updates on this Website
Recent documents from LLR APC and TAS
SBAR LLR ICB Recommendations Clenil Discontinuation(615 KB)
Date added: 15th Sep 2026
LLR ICB Position Statement Patient Self-Testing of INR for warfarin monitoring(123 KB)
Date added: 2nd Sep 2026
Cellulitis Teicoplanin Pathway(1 MB) - Guidelines
Date added: 21st Jul 2020
Recording Medicines Prescribed And Issued By Other Healthcare Providers(411 KB) - Guidelines
Date added: 9th Mar 2018
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more